Comparative Study of Systemic Inflammatory Responses in Psoriasis Vulgaris and Mild to Moderate Allergic Contact Dermatitis

Abstract

Background: Psoriasis vulgaris (PV) is associated with low-grade systemic inflammation. Objective: Cytokines’ and growth factors’ serum patterns in patients with PV, allergic contact dermatitis (ACD) and healthy subjects were investigated to describe and compare systemic inflammatory responses in these diseases. Methods: A total of 12 inflammation-sensitive biomarkers were analyzed simultaneously by means of the Evidence Investigator™ biochip technology. Results: In PV, proinflammatory tumor necrosis factor (TNF)-α, interferon (IFN)-γ, interleukins (IL)-1β, -2, -6, -8, and monocyte chemoattractant protein (MCP)-1 were elevated. In ACD, 2 markers, TNF-α and MCP-1, were increased, and regulatory cytokine IL-10 was decreased. Proinflammatory IL-2 had the strongest correlations with other pro- as well as anti-inflammatory cytokines in PV and ACD, whilst IL-6 correlated positively with the Psoriasis Area and Severity Index. Growth factors’ levels correlated with MCP-1, but only in PV. Conclusion: Although psoriasis induces a more variegated proinflammatory systemic response, ACD is likewise associated with a systemic increase in inflammatory mediators.

Allergic Contact Dermatitis Is Associated with Significant Oxidative Stress

“…Therefore, decreased IL-10 concentrations, found in this and some previous studies [17, 22], might indicate the utilization of this cytokine in downregulation of allergic contact dermatitis.…”

Antipsychotic treatment is associated with inflammatory and metabolic biomarkers alterations among first‐episode psychosis patients: A 7‐month follow‐up study

“…Biochip array technology (Randox Biochip, RANDOX Laboratories Ltd, Crumlin, UK, Metabolic Syndrome Array I for Evidence Investigator™) was used to perform simultaneous quantitative detection of multiple analytes from a single serum sample of CS or FEP patient as we have described previously (Kaur, Zilmer, Leping, & Zilmer, 2012).…”

The role of PGRN in musculoskeletal development and disease

“…The application of this PGRN-derivative can act in a myriad of clinical conditions whose patho-mechanism involves upregulation and a disproportion of TNFa signaling and its resultant induction of inflammatory processes, including but not limited to neuro-degenerative and inflammatory diseases, Crohn’s disease (74), IBD (75), and ulcerative colitis (76), asthma (77), dermatitis and psoriasis (78), and rheumatoid arthritis (79). Attstrin’s effects have been studied in rheumatoid arthritis (50) and dermatitis models (27), and its clear signaling interception and competitive inhibition of TNFa via TNFR1/2 binding proposes it as a highly promising therapeutic target for the prevention of inflammatory diseases affecting the musculoskeletal system.…”